The FDA expanded the indications for dupilumab (Dupixent, Regeneron/Sanofi) to include treatment of children with eosinophilic esophagitis who are as young as 1 year and who weigh at least 15 kg.
This is the first EoE treatment approved for this age group. Dupilumab, which targets the interleukin-4 and -13 pathways, was already approved in May 2022 for treatment of EoE in patients 12 years of age and older who weigh at least 40 kg.
This expanded indication follows positive results from